Aptose doses first patient at 120 mg tuspetinib in TUSCANY triplet trial after positive safety review

Aptose Biosciences Inc.

CSRC cleared escalation to 120 mg TUS based on safety from 40 mg and 80 mg cohorts.
First patient dosed at 120 mg as part of TUS+VEN+AZA triplet frontline therapy for AML.
No prolonged myelosuppression or dose-limiting toxicities reported in first two cohorts.
Complete remissions and MRD negativity observed across diverse AML mutations.
Updated data to be presented at EHA 2025 congress (June 12-15) in Milan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.